Abstract PTU-33 Table 1 shows degree of adherence to the SBP and the prevalence of dysplastic/malignant change

Length (cm)	N	Adherence to Seattle protocol (%)	Indefinite for dysplasia (%)	Low-grade dysplasia (%)	High-grade dysplasia (%)	Malignancy* (%)
<3	406	94.44	0.51	0.51	1.52	0
3 to 8	666	82.92	5.11	5.05	1.49	0.36
>8	182	76.57	4.80	2.28	4.35	4.59

*All malignancy were adenocarcinoma.

diagnosis of 61; 64 years old for females. Barrett's length was not recorded in 81 cases and excluded from the final analysis.

Duodenal inspection findings were: Normal - 96.2%; Duodenitis - 3.4%; Duodenal ulcer (clean base) - 0.4%

Conclusions Our audit demonstrates:

- As Barrett's length increases, the risk of high grade dysplasia and malignancy increases, but conversely, the degree of adherence to the SBP decreases.
- Duodenal inspection rarely identified significant pathology, and the management of the Barrett's oesophagus superseded the management any duodenal findings.

We conclude that in the absence of new symptoms suggesting duodenal pathology, Barrett's surveillance should be considered a distinct examination from a diagnostic OGD. The endoscopist should not need to inspect the duodenum, allowing more time to focus on careful oesophageal inspection and strict adherence to the SBP.

REFERENCES

1. Fitzgerald RC *et al.* *Gut* 2013;**0**:1–36.
2. Beg S *et al.* *Gut* 2017;**0**:1–4.

PTU-34 SMALL BOWEL CAPSULE ENDOSCOPY: A COMPARISON AGAINST EUROPEAN SOCIETY OF GASTROINTESTINAL ENDOSCOPY PERFORMANCE MEASURES

Olivia Etter*, Rukmini Jagdish, Peter Matthews, Emma Johnston, Samuel Pannick. *West Middlesex University Hospital, London, UK*

10.1136/gutjnl-2021-BSG.107

Introduction In 2019, the European Society of Gastrointestinal Endoscopy (ESGE) published its first performance measures⁺ for use by small bowel capsule endoscopy (SBCE) services. There is no published data on performance of UK SBCE services against these metrics. We aimed to evaluate the quality of the SBCE service at a district general hospital.

Method A standardised proforma was designed to capture the performance metrics listed by ESGE. Data was collected retrospectively from SBCEs performed between January 2019 and September 2020 at a single hospital site. Data was drawn from the SBCE procedure report, reported by a consultant gastroenterologist, using Miroview software, and from electronic medical records. Discrepancies were resolved by consensus by two reviewers.

Results 50 patients underwent SBCE in the study period; 1 was excluded from the study due to a referral error. We included 49 patients, of which 30 were male, with a median age of 62. Our SBCE service met 5/10 of the targets (Table 1). 'Lesion detection' was the performance metric met least

Abstract PTU-34 Table 1 SBCE service results against the ESGE quality metrics

Domain	Performance metric	Minimum (≥%)	Target (≥%)	Result % (n)
Pre-procedure	Indication for SBCE	95	95	100 (49)
	Adequate bowel preparation	95	95	86 (26)
	Patient selection	95	95	77 (7)
Procedure completion	Caecum/stoma visualised	80	95	84 (41)
Pathology identification	Lesion detection rate	50	50	39 (19)
	Timing of SBCE for overt bleeding	90	90	83 (10)
	Use of standard terminology	90	90	100 (49)
Pathology management	Reading speed of SBCE	90	95	0 (0)
	Appropriate referral for DAE	75	90	80 (4)
Complications	Capsule retention rate	<2	<2	0 (0)

often (39%), with 'use of standard terminology', 'indication for SBCE' and 'capsule retention rate' being the best met metrics (100%). Data on 'reading speed' was not collected.

Conclusion This analysis is the first to compare a UK SBCE service against newly-released ESGE quality improvement criteria, and the first to report patient-level data from any service.

We identified areas of good performance and targets for quality improvement. The Miroview application used by the service for recording reports encourages data capture for some of these quality metrics. Others, such as reading speed and adequacy of bowel preparation need to be more actively recorded when the procedure is reported. A proforma has been devised to assist high quality capsule reporting for the future.

The results from this single-centre study support the need for a larger, multi-centre UK study, assessing UK SBCE service quality on a national level.

⁺Spada C, McNamara Det al. Performance measures for small-bowel endoscopy: a European Society of Gastrointestinal Endoscopy (ESGE) Quality Improvement Initiative. *Endoscopy*. 2019;**51**(06):574-598.

PTU-35 ENDOSCOPIC BIPOLAR RADIOFREQUENCY ABLATION FOR TREATING MALIGNANT BILIARY OBSTRUCTION: SYSTEMATIC REVIEW AND META-ANALYSIS

¹Fiona Beyer, ¹Stephen Rice, ¹Giovany Orozco-Leal, ¹Madeleine Still, ¹Hannah O'Keefe, ¹Nicole O'Connor, ¹Akville Stoniute, ¹Dawn Craig, ²Stephen Pereira, ³Louise Carr, ^{1,3}John Leeds*. ¹Population Health Sciences Institute, Newcastle Upon Tyne, UK; ²University College London Institute, London, UK; ³Newcastle Upon Tyne Teaching Hospitals, Newcastle Upon Tyne, UK

10.1136/gutjnl-2021-BSG.108

Introduction Early evidence suggests using radiofrequency ablation (RFA) as an adjunct to stenting may improve outcomes in patients with malignant biliary obstruction. RFA can be deployed either at the initial stent insertion or to clear tumour ingrowth in a previously placed stent.

Methods To assess the clinical and cost effectiveness and potential risks of RFA for malignant biliary obstruction.